US/Italian Multicenter Collaboration

McCullough PA, Kelly RJ, Ruocco G, Lerma E, Tumlin J, Wheelan KR, Katz N, Lepor NE, Vijay K, Carter H, Singh B, McCullough SP, Bhambi BK, Palazzuoli A, De Ferrari GM, Milligan GP, Safder T, Tecson KM, Wang DD, McKinnon JE, O'Neill WW, Zervos M, Risch HA. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. Am J Med. 2020 Aug 7:S0002-9343(20)30673-2. doi: Epub ahead of print. PMID: 32771461; PMCID: Multicenter CollaborationAcademic Medical CentersPublic HeathIntegrated Health SystemsCommunity PracticeBiotech IndustrySpecialtiesInternal MedicineCritical CareNephrologyCardiologyElectrophysiolog yInfectious DiseasesOphthalmologyEpidemiologyBiostat isticsDay 0 Symptom Onset 7 days 14 days 21 days 30 days Untreated Mortality RiskCoughDifficulty BreathingFeverSore ThroatMalaiseBody AchesNasal StuffinessLoss of tasteAnorexiaNauseaDiarrheaChest Heaviness/PainDyspneaDesaturationSystemi c ThromboembolismOff-Target AntiviralsCorticosteroidsAntiplatelet Drugs/AntithromboticsSARS-CoV-2 Nasal PCR+Oral PCR/Ag+ D-dimer Hs-CRP LymphocytesAmbulatory Phase Hospitalization Phase DeathMcCullough PA, Fourth-Quarter 2020 COVID-19 Drug and Diagnostic Developments A Virtual Conference Monday, November 2nd2020, 9:00am -6.

Favipiravir 600 mg po bid + AZM 250 mg po bid or. IVM 6-12 mg po qd x 1 -3 days + AZM 250 mg po bid or +Doxy 100 mg po bid . Adapted from McCullough PA, Kelly RJ, Ruocco G, Lerma E, Tumlin J, Wheelan KR, Katz N, Lepor NE, Vijay K, Carter H, Singh B, McC ullough SP, Bhambi BK, Palazzuoli A, De Ferrari GM, Milligan

Loading..

Information

Related search queries